Table 5.
Summary statistics of time-to-event (TTE) endpoints by extent of disease
| TTE endpoint | N | Events | Point estimate | 90% Confidence interval | |
|---|---|---|---|---|---|
| Time to progression | |||||
| Extent of disease | |||||
| Minimal | 4 | 4 | |||
| Median | 12.8 Months | 4.3 Months | 14.7 Months | ||
| 6 Month rate | 72% | 30% | 100% | ||
| 12 Month rate | 53% | 12% | 94% | ||
| Extent of disease | |||||
| Extensive | 25 | 22 | |||
| Median | 7.0 Months | 3.3 Months | 8.5 Months | ||
| 6 Month rate | 57% | 40% | 73% | ||
| 12 Month rate | 27% | 11% | 43% | ||
| Overall Survival | |||||
| Extent of disease | |||||
| Minimal | 4 | 4 | |||
| Median | 18.9 Months | 7.2 Months | 24.5 Months | ||
| 6 Month rate | 100% | a | 100% | ||
| 12 Month rate | 70% | 29% | 100% | ||
| Extent of disease | |||||
| Extensive | 25 | 22 | |||
| Median | 11.2 Months | 9.1 Months | 16.4 Months | ||
| 6 Month rate | 82% | 69% | 96% | ||
| 12 Month rate | 47% | 30% | 63% | ||
Extent of disease was missing for 2 of the 31 patients enrolled.
There were only 2 patients with superscan extent of disease, so they have been included with the 23 extensive disease patients for statistical analysis purposes.
a
Cannot be calculated as no event took place before 10 months.